Caris Life Sciences Launches National Ad Featuring Jordan Spieth to Highlight AI's Role in Early Cancer Detection

The new campaign shows how AI-powered technology can help improve performance and how advanced molecular science may help find cancer earlier.

IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a company that combines technology and biology, announced today that it has launched the second advertisement in a series promoting Caris Detect™. This blood test is designed to help detect several types of cancer early. The new advertisement features Jordan Spieth, a professional golfer who has won three major championships.

The campaign explains that modern technology can measure almost every part of an athlete's performance. Similar technology may also help find cancer early, when treatment has the best chance of working. The new advertisement shows how AI has changed golf by studying millions of golf swings and many other pieces of information to help players improve. It also shows how Caris uses its many years of experience in molecular science and AI to look for signals linked to cancer in a small blood sample.

"Artificial intelligence is changing almost every part of our lives, from how we work and talk to each other to how athletes improve their performance," said David Dean Halbert, Founder, Chairman and Chief Executive Officer of Caris Life Sciences. "At Caris, we believe one of the most important uses of AI is helping improve early cancer detection. Caris Detect combines a detailed study of molecules with advanced AI. Our goal is to help make a future possible in which cancer can be found early, when there is the best chance of curing it."

"Every golfer wants to gain an advantage. We use technology to measure everything from how fast the ball travels to how much it spins, because better information helps us make better choices. That's what stood out to me about Caris Detect. If advanced AI can help us understand our golf game, it should also help us understand our health better. I'm proud to support efforts to raise awareness about why finding cancer early matters," said Jordan Spieth, a professional golfer who has won three major championships.

Unlike tests that look at only a small number of biological markers, Caris Detect™ uses a highly detailed form of Whole Genome Sequencing (WGS) to examine all 23,000 genes. It also uses Whole Transcriptome Sequencing (WTS) and advanced AI to study a wide range of cancer-related signals in both DNA and RNA. DNA carries genetic instructions, while RNA helps cells use those instructions. Caris says this broad approach is designed to give a more complete picture of the biology of early cancer. By studying one blood sample, the test aims to find patterns linked to cancer and help detect it earlier, when treatment is more likely to work.

People who want to learn more about Caris Detect can visit CarisDetect.com.

About Caris Detect
Caris Detect™ is a blood test designed to help find signs linked to several types of cancer at an early stage. It uses highly detailed Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced AI to study a wide range of molecular information. The goal is to find signals linked to cancer as early as possible, when the disease may be easiest to treat successfully.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a company that develops and sells technology-based solutions combining biology and data science to improve healthcare. It studies molecules in the body using Whole Genome, Whole Exome and Whole Transcriptome Sequencing, along with advanced AI and machine learning. The company has built a large database that combines medical information with genetic and molecular data, as well as the computing systems needed to study the complex biology of disease. By bringing together modern DNA sequencing, AI, machine learning and powerful computers, Caris has built a platform for developing advanced precision medicine tests and tools. These are intended to help detect and diagnose disease, monitor patients, guide treatment choices and support drug development.

Caris was founded to help use precision medicine to improve people's lives. Its headquarters are in Irving, Texas, and it has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland. Caris and its distribution partners provide services in the United States and other countries.

Forward Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These are statements about what may happen in the future, rather than facts about the past. They include statements about our business, products and services, plans, goals, industry trends, financial outlook and guidance. Words that may identify these statements include "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," and "continue," along with similar words.

You should not treat forward-looking statements as promises or predictions of what will happen. We believe our expectations are reasonable based on the information available to us now, but we cannot promise that the future results, discoveries, activity levels, performance, events or circumstances described in these statements will happen. These statements involve known and unknown risks and uncertainties, including some that we cannot control. The risks that could cause our actual results to differ greatly from what these statements say or suggest include, among other things: continued development, performance and sales of Caris Detect; changes in the precision medicine industry; our future financial performance, operating results and other business measures; the development, testing and clinical validation of future products and services, their timing and performance, and the products and services of our competitors; whether customers and the market accept our products and services, including preventive tests as well as tests used to diagnose disease, and whether we can meet demand; rapid changes in competition; decisions by insurance companies and other third-party payers about covering our services and paying for them; the effect on future sales volumes of continuing our plan to reorganize and expand our sales team; risks involving how we manage, store and process data and our ability to bring AI and advanced data analysis tools into our work; our ability to protect and strengthen our intellectual property; regulatory rules, decisions and approvals, including the timing and conditions of approvals for our products and services and our application for New York State Department of Health approval for Caris Assure; our reliance on outside suppliers; risks involving data security, patient privacy, healthcare data protection rules and possible cyberattacks on our data systems; our compliance with laws and regulations; the results of government investigations and legal cases; risks related to our debt; our ability to hire and keep important employees; and other risks, uncertainties and factors described in the section called "Risk Factors" and elsewhere in our Annual Report on Form 10-K, filed on March 3, 2026, and in other documents we file with the SEC from time to time. We are not required to update these forward-looking statements when events, circumstances or our beliefs change after the date of this press release, unless the law requires us to do so.

Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606

View the original content and download multimedia: https://www.prnewswire.com/news-releases/caris-life-sciences-launches-new-national-commercial-featuring-jordan-spieth-highlighting-the-power-of-artificial-intelligence-in-early-stage-cancer-detection-302912015.html

SOURCE Caris Life Sciences